G1 Therapeutics, Inc.
GTHX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 60.8% | 63% | -30.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.3% | 92.7% | 93.6% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -41.6% | -263% | -452.6% | -210.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -58.1% | -287.6% | -471.3% | -219.2% |
| EPS Diluted | -0.93 | -3.38 | -3.54 | -2.62 |
| % Growth | 72.5% | 4.5% | -35.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |